| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
144,770,000 |
| Market
Cap: |
550.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.335 - $8.78 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adaptive Biotechnologies is a commercial-stage company developing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s immune medicine platform applies its main technologies to read the genetic code of a patient's immune system. Co.'s clinical diagnostic product, clonoSEQ, is authorized by the Food and Drug Administration for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
181,388 |
181,647 |
370,810 |
539,321 |
| Total Sell Value |
$624,469 |
$625,539 |
$2,103,520 |
$3,574,731 |
| Total People Sold |
8 |
8 |
9 |
11 |
| Total Sell Transactions |
8 |
9 |
13 |
36 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pellini Michael J |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
8,193 |
|
- |
|
| Conroy Kevin T |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
8,193 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
8,193 |
|
- |
|
| Trigg Leslie |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
11,132 |
|
- |
|
| Neupert Peter M |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
8,193 |
|
- |
|
| Burris Michelle |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
8,193 |
|
- |
|
| Owen Katey Einterz |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
11,132 |
|
- |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-01-07 |
4 |
S |
$23.32 |
$23,810 |
D/D |
(1,021) |
50,833 |
|
68% |
|
| Cohen Chad M |
Chief Financial Officer |
• – – |
2021-12-22 |
4 |
AS |
$30.00 |
$300,000 |
D/D |
(10,000) |
21,604 |
|
-70% |
|
| Cohen Chad M |
Chief Financial Officer |
• – – |
2021-12-22 |
4 |
OE |
$7.27 |
$72,700 |
D/D |
10,000 |
31,604 |
|
- |
|
| Taylor Stacy L |
SVP and General Counsel |
• – – |
2021-12-22 |
4 |
AS |
$30.00 |
$460,140 |
D/D |
(15,338) |
15,036 |
|
-70% |
|
| Taylor Stacy L |
SVP and General Counsel |
• – – |
2021-12-22 |
4 |
OE |
$6.55 |
$106,974 |
D/D |
15,338 |
30,374 |
|
- |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-11-18 |
4 |
AS |
$31.36 |
$9,408 |
D/D |
(300) |
69,360 |
|
-49% |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-11-18 |
4 |
OE |
$6.55 |
$1,965 |
D/D |
300 |
69,660 |
|
- |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-11-17 |
4 |
AS |
$32.05 |
$118,585 |
D/D |
(3,700) |
69,360 |
|
-57% |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-11-17 |
4 |
OE |
$6.55 |
$24,235 |
D/D |
3,700 |
73,060 |
|
- |
|
| Piskel Kyle |
Principal Accounting Officer |
• – – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,837 |
6,699 |
|
- |
|
| Cohen Chad M |
Chief Financial Officer |
• – – |
2021-11-10 |
4 |
AS |
$33.93 |
$169,650 |
D/D |
(5,000) |
21,604 |
|
-61% |
|
| Cohen Chad M |
Chief Financial Officer |
• – – |
2021-11-10 |
4 |
OE |
$7.27 |
$36,350 |
D/D |
5,000 |
26,604 |
|
- |
|
| Cohen Chad M |
Chief Financial Officer |
• – – |
2021-11-09 |
4 |
AS |
$36.03 |
$180,150 |
D/D |
(5,000) |
21,604 |
|
-62% |
|
| Cohen Chad M |
Chief Financial Officer |
• – – |
2021-11-09 |
4 |
OE |
$7.27 |
$36,350 |
D/D |
5,000 |
26,604 |
|
- |
|
| Piskel Kyle |
Principal Accounting OfficerOf |
• – – |
2021-10-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,862 |
|
-68% |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-10-21 |
4 |
AS |
$33.73 |
$124,801 |
D/D |
(3,700) |
69,360 |
|
-64% |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-10-21 |
4 |
OE |
$6.55 |
$24,235 |
D/D |
3,700 |
73,060 |
|
- |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2021-10-20 |
4 |
AS |
$33.71 |
$124,727 |
D/D |
(3,700) |
69,360 |
|
-61% |
|
867 Records found
|
|
Page 5 of 35 |
|
|
0.30 (8.57%) 
